Menu

Catalog of the Small Intestine Reveals New Cell Subtypes

Single-cell analyses from mouse samples detail the changes in cell distribution during infections.

Nov 8, 2017
Kerry Grens

ISTOCK, WWINGResearchers have developed a taxonomy of the cell types in the mouse small intestine from more than 53,000 single-cell RNA profiles. The endeavor reveals previously unknown cellular subtypes, suggests reclassifying others, and details the changes in the lining of the small intestine during bacterial and parasite infections, according to results published today (November 8) in Nature.

“We see this atlas providing a foundation for investigating many different questions about the pathology in the gut, effects of drug-induced gut toxicities and for identifying and examining important cells, interactions, and biomarkers,” coauthor Ramnik Xavier, a member of the Broad Institute of MIT and Harvard University, says in a press release.

Xavier and colleagues collected tissue from the small intestine epithelium of mice and built transcriptional profiles using RNAseq. One of the striking revelations was the discovery of new subtypes of tuft cells, the sensory cells that bear taste receptors to detect pathogens. “We were surprised to see that expression of the gene TSLP—which encodes a cytokine long known to be involved in epithelial-induced inflammation—was exclusive to a particular subset of tuft cells,” coauthor Adam Haber, a postdoc at the Broad and MIT, says in the release. “This suggests a significant ‘lookout’ role for these recently characterized cells.”

See “Opinion: How to Define Cell Type”

The researchers also infected mice with either Salmonella or a roundworm, Heligmosomoides polygyrus, then analyzed a few thousands cells individually to look for infection-related changes. They observed a boost in the expression of genes related to inflammation and immune defense, as well as a change in the overall cellular makeup of the intestine. After bacterial infection, for instance, mice had more mature enterocytes and fewer stem cells than controls. In response to the worm, mice had more so-called goblet cells—which, the authors note, respond to the parasite—and fewer enterocytes.

“Although many studies have demonstrated that goblet cells and, more recently, that tuft cells accumulate and respond to parasites, our analysis reveals that this restructuring of the epithelial barrier is specific to the identity of the pathogen,” the authors write in their report.

See “Gut Feeling”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.